ArticleFrontiers in pharmacology2022

A novel 16-gene alternative mRNA splicing signature predicts tumor relapse and indicates immune activity in stage I-III hepatocellular carcinoma.

Xu-Xiao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.